An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Inclusion Criteria: * Provision to sign and date the consent form * Stated willingness to comply with all study procedures and be available for the duration of the study * Be a woman aged ≥18 years of age * Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 * Patients must have a confirmed diagnosis of high-grade serous or endometrioid EOC, primary peritoneal cancer, or fallopian tube cancer * Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of prior platinum therapy (not inclusive of current/most recent platinum therapy) * Patients must have had documented complete or partial response, or stable disease, as defined by RECIST 1.1, from last line of platinum therapy * Patients must have available archival tissue block or slides to confirm FRalpha positivity * Patients' tumor must have FRalpha high or medium expression * Prior anticancer therapy: * Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease. * Most recent prior chemotherapy regimen must have consisted of at least 4 completed cycles and no more than 8 completed cycles * Most recent prior chemotherapy regimen must have been platinum based * Patients must have had testing for BRCA mutation (tumor or germline) and, if positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy * Neoadjuvant +/…